{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:51:15Z","timestamp":1793645475251,"version":"4.5.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100025561","name":"Glimmer of Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcyt.2025.06.011","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:42:05Z","timestamp":1755128525000},"page":"1279-1289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3519-1938","authenticated-orcid":false,"given":"Vera S.","family":"Donnenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-099X","authenticated-orcid":false,"given":"John","family":"Lister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene L.","family":"Briedenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3935-5316","authenticated-orcid":false,"given":"Patrick L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-2613","authenticated-orcid":false,"given":"David L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-3330","authenticated-orcid":false,"given":"Albert D.","family":"Donnenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcyt.2025.06.011_bib0001","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","article-title":"Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study","volume":"6","author":"Topalian","year":"1988","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jcyt.2025.06.011_bib0002","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jcyt.2025.06.011_bib0003","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2212small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer discovery"},{"issue":"16","key":"10.1016\/j.jcyt.2025.06.011_bib0004","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jcyt.2025.06.011_bib0005","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0006","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.2147\/DDDT.S175113","article-title":"Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des Devel Ther."},{"issue":"Suppl._1","key":"10.1016\/j.jcyt.2025.06.011_bib0007","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1182\/blood-2019-131300","article-title":"Phase 1 study of on site manufactured anti-CD19 CAR-T cells: responses in subjects with rapidly progressive refractory lymphomas","volume":"134","author":"Caimi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0008","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/S1525-0016(16)33268-3","article-title":"459. Evaluation of Miltenyi ExpAct and TransAct CD3\/28 beads for CAR-T cell manufacturing","volume":"24","author":"Wang","year":"2016","journal-title":"Molecular Therapy"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0009","series-title":"Flow cytometry protocols. methods in molecular biology","first-page":"251","article-title":"Rare event detection and analysis in flow cytometry: bone marrow mesenchymal stem cells, breast cancer stem\/progenitor cells in malignant effusions, and pericytes in disaggregated adipose tissue","volume":"699","author":"Zimmerlin","year":"2011"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1157697","article-title":"A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells","volume":"14","author":"Donnenberg","year":"2023","journal-title":"Frontiers in immunology"},{"issue":"0","key":"10.1016\/j.jcyt.2025.06.011_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2015.03.012","article-title":"Coping with artifact in the analysis of flow cytometric data","volume":"82","author":"Donnenberg","year":"2015","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.jcyt.2025.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.115.6.1592","article-title":"Studies on T cell clonal expansion. I. Suppression of killer T cell production in vivo","volume":"115","author":"Kamat","year":"1975","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0013","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.011_bib0014","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of malignant pleural effusions","volume":"162","author":"Antony","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1404373","article-title":"A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting","volume":"15","author":"Donnenberg","year":"2024","journal-title":"Front Immunol"},{"issue":"60","key":"10.1016\/j.jcyt.2025.06.011_bib0016","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.011_bib0017","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2567.2007.02728.x","article-title":"Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages","volume":"124","author":"Oviedo-Orta","year":"2008","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.011_bib0018","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00262-021-02886-8","article-title":"TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer","volume":"70","author":"Liang","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.31466","article-title":"Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell carcinoma","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.jcyt.2025.06.011_bib0021","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.jcyt.2025.06.011_bib0022","doi-asserted-by":"crossref","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-\u03b3 production of natural killer cells via \u03b2-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.011_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.imbio.2015.08.003","article-title":"TIGIT negatively regulates inflammation by altering macrophage phenotype","volume":"221","author":"Chen","year":"2016","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.011_bib0024","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomarker Res"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.011_bib0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"issue":"48","key":"10.1016\/j.jcyt.2025.06.011_bib0026","doi-asserted-by":"crossref","first-page":"eadh9879","DOI":"10.1126\/sciadv.adh9879","article-title":"Engineered IL-7 synergizes with IL-12 immunotherapy to prevent T cell exhaustion and promote memory without exacerbating toxicity","volume":"9","author":"Kang","year":"2023","journal-title":"Science Advances"},{"issue":"12","key":"10.1016\/j.jcyt.2025.06.011_bib0027","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.4049\/jimmunol.2001077","article-title":"IL-7 and IL-15 levels reflect the degree of T cell depletion during lymphopenia and are associated with an expansion of effector memory T cells after pediatric hematopoietic stem cell transplantation","volume":"206","author":"Kielsen","year":"2021","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.jcyt.2025.06.011_bib0028","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.011_bib0029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.011_bib0030","article-title":"Intra-pleural and intra-peritoneal tocilizumab therapy for managing malignant pleural effusions and ascites: The Regional Immuno-Oncology Trial (RIOT)-2 study protocol","volume":"1","author":"Park","year":"2024","journal-title":"Surg Oncol Insight"},{"issue":"24","key":"10.1016\/j.jcyt.2025.06.011_bib0031","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","article-title":"Combination nivolumab, CD137 agonism, and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"28","author":"Hall","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.06.011_bib0032","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2340\/1651-226X.2024.40495","article-title":"NIVO-TIL: combination anti-PD-1 therapy and adoptive T-cell transfer in untreated metastatic melanoma: an exploratory open-label phase I trial","volume":"63","author":"L'Orphelin","year":"2024","journal-title":"Acta Oncol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:09:37Z","timestamp":1772888977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1465324925007625"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.011","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fast tumor-infiltrating lymphocytes (TILs): rapid manufacture of an adoptive cellular therapeutic from pleural infiltrating T cells for intrapleural administration","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}